
Please try another search
In the latest trading session, DexCom (DXCM) closed at $247.64, marking a -1.89% move from the previous day. This move was narrower than the S&P 500's daily loss of 9.51%. Elsewhere, the Dow lost 9.99%, while the tech-heavy Nasdaq lost 9.44%.
Coming into today, shares of the medical device company had gained 2.61% in the past month. In that same time, the Medical sector lost 12.7%, while the S&P 500 lost 18.22%.
DXCM will be looking to display strength as it nears its next earnings release. In that report, analysts expect DXCM to post earnings of $0.11 per share. This would mark year-over-year growth of 320%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $357.53 million, up 27.46% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.25 per share and revenue of $1.78 billion, which would represent changes of +22.28% and +20.32%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for DXCM. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 21.08% higher. DXCM currently has a Zacks Rank of #1 (Strong Buy).
Investors should also note DXCM's current valuation metrics, including its Forward P/E ratio of 112.19. This valuation marks a premium compared to its industry's average Forward P/E of 28.62.
Investors should also note that DXCM has a PEG ratio of 3.06 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 2.23 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 53, which puts it in the top 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Over the weekend I warned about the weakness in the Semiconductor sector (SMH). I also wrote about Granny Retail XRT, and how important it is for that sector to stay alive. Both...
Two weeks ago, the rumor mill ramped up again about the potential restructuring of Intel Corporation (NASDAQ:INTC). The probing balloons centered around Taiwan Semiconductor...
More than a century ago, then-Representative William McKinley pursued an aggressive tariff strategy that sought to protect American industry and reduce reliance on foreign...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.